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INTRODUCTION
Ovarian cancer is the second most common gyne-
cological cancer in Western countries with a high
mortality rate. In Indonesia, ovarian cancer is the
third most common gynecological cancer.1,2 Unlike
breast and cervical cancer, there is no effective
screening method for ovarian cancer. The applica-
tion of certain screening to high risk women is still
controversial.3,4
The incidence rate was varied worldwide ac-
cording to geographic location, where as the rates
in Asia were lower than Western countries. Highest
incidence for more than 8 per 100,000 was found
in developed countries.5,6 Though Japan and Hong-
kong had the lowest incidence, there was an in-
crease about 15-25% every 5 years.5 Generally,
ovarian cancer had been diagnosed in older wo-
men with the incidence of 61.3 per 100,000 in 75-
and 79-year-old women.7 Moreover, the histopa-
thology was varied according to geographic loca-
Abstract
Objective: To describe the incidence of ovarian cancer and its char-
acteristic in Dr. Cipto Mangunkusumo Hospital in the last 5 years.
Method: This was cross sectional study design. The data was col-
lected from Gynecology Oncology Division Cancer Registry and Dr.
Cipto Mangunkusumo Hospital medical record from January 2009 to
December 2013; follow up was performed to know the 4-years sur-
vival rate.
Result: There were 98 subjects in this study. The majority incidence
of ovarian cancer was 45-54 years old (33.6%); the incidence of
ovarian cancer decreased with the increased number of parity; the
majority histotype was epithelial (76.5%); and most of them were
diagnosed on advanced stage (55.1%). The 4-year survival rate for
epithelial type was 77%; germinal type was 83.3%; and stromal type
was 100%. Based on therapy, the 4-year survival rate was 84.1% for
surgical only; 83.3% in adjuvant chemotherapy group; and 68.4% in
neoadjuvant chemotherapy. In the group of adjuvant chemothera-
py, there was 63% patients with complete response and 41.2% pa-
tients with complete response in neoadjuvant chemotherapy.
Conclusion: The highest incidence of ovarian cancer in Dr. Cipto
Mangunkusumo Hospital belongs to the age of reproductive women
(≤ 55 years old) with the highest incidence occurs in nulliparity wo-
men. Most of the ovarian cancer cases are diagnosed in advanced
stage (stage III-IV).
[Indones J Obstet Gynecol 2016; 4-2: 101-106]
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Abstrak
Tujuan: Mengetahui gambaran umum kanker ovarium di RSCM 5 ta-
hun terakhir beserta faktor-faktor yang berhubungan dengan kankerovarium.
Metode: Penelitian ini menggunakan desain potong lintang. Peneli-tian ini mengambil data pasien kanker ovarium di Cancer Registry
divisi Ginekologi Onkologi dan rekam medis di RSCM pada periode
Januari 2009 - Desember 2013, dilakukan follow up untuk mengetahuikesintasan hidup selama 4 tahun.
Hasil: Terdapat 98 subyek penelitian. Pada penelitian ini didapatkan
insidensi kanker ovarium terbanyak pada usia 45-54 tahun (33,6%),
insidensi kanker ovarium menurun dengan bertambahnya jumlahanak, sebagian besar kanker ovarium merupakan tipe epitelial
(76,5%) dan sebagian besar pasien didiagnosa pada stadium lanjut
(55,1%). Kesintasan hidup 4 tahun pasien kanker ovarium tipe epi-telial 77%; tipe germinal 83,3%; tipe stroma 100%. Kesintasan hidup
4 tahun dengan terapi pembedahan 84,1%; pembedahan disertai ke-moterapi adjuvan 83,3%; kemoterapi neoadjuvan sebelum pembeda-
han 68,4%. Terdapat 63% respon komplit pada kelompok kemoterapi
adjuvan; dan 41,2% pada kelompok kemoterapi neoadjuvan.
Kesimpulan: Insidensi kanker ovarium di RSCM lebih tinggi pada
pasien usia reproduksi (≤ 55 tahun); insidensi kanker ovarium di RSCMlebih tinggi pada pasien nulipara; dan sebagian besar pasien kanker
ovarium di RSCM didiagnosis pada stadium lanjut (stadium III dan IV).
[Maj Obstet Ginekol Indones 2016; 4-2: 101-106]
Kata  kunci: histologi, kanker ovarium, kesintasan, paritas, respon,
stadium, terapi, usia
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tion. In Western countries, the rates of ovarian
germ cell tumor were less than 5%; while in Asia
and Africa-American, the incidence rates achieved
15%.8
The definitive therapy for ovarian cancer is sur-
gery with or without chemotherapy. It can be given
as neo-adjuvant or adjuvant therapy.9 Several stu-
dies showed that chemotherapy as adjuvant the-
rapy had improved overall survival rate and the
recurrence of free survival.10 However, the admi-
nistration of chemotherapy as neo-adjuvant was
still controversial.8
We conducted this study because there were dif-
ferences of ovarian cancer risk factors in every re-
gion. This study aims to evaluate the incidence of
ovarian cancer in Dr. Cipto Mangunkusumo Hospi-
tal based on age, menarche and number of parity.
Due to the differences of ovarian cancer mortality
rate in every region, we also evaluated the survi-
val rate based on histopathology, therapy and res-
ponse rate.
METHODS
This was a cross sectional study design based on
cancer registry. The inclusion data were ovarian
cancer cases registered in cancer registry from 1st
January 2009 to 31st December 2013 and had
medical record. The exclusion criteria was border-
line ovarian tumor. The initial step was to record
the register number, medical record number, pa-
tient identity, parity, age of newly diagnosed cases,
age of menarche, staging, histopathology result, cy-
tology result, treatment regimen and response. The
missing data from cancer registry were completed
through medical record data. Subjects were fol-
lowed-up until 30th November 2014.
All the data were executed using SPSS 21. The
statistical data included descriptive categorical
analysis for the incidence of ovarian cancer cases
based on reproductive age status, menarche age,
parity, cytology result, histopathology, treatment
regimen and stage; while survival rate based on
stage, histopathology, response rate from each
treatment regimen would be analyzed using Kap-
plan Meier method. Survival analysis was subjects
in the beginning period, subjects under censored
and subjects under events from period. Ethical
committee had approved the study with the re-
gister of 611/UN2.F1/ETIK/2014.
RESULTS
There were 395 ovarian cancer subjects registered
in cancer registry from 2009 to 2013. All data were
tracked to hospital medical record; the incomplete
data were excluded from the study. All of patients
who had been diagnosed in 2009 were being ex-
cluded because of missing medical record. More-
over, most of the medical records were incomplete.
There were only 98 patients fulfilled the complete
data recorded in cancer registry and medical re-
cord. It consisted of 15 patients in 2010, 19 pa-
tients in 2011, 29 patients in 2012 and the rest 35
patients in 2013. The cytology documentation that
was not recorded in cancer registry and medical
record were tracked to Pathology Anatomy Depart-
ment Dr. Cipto Mangunkusumo Hospital.
In order to evaluate the survival rate, the lost of
follow-up subjects were updated based on family
members’ recall. However, this method was not eli-
gible to complete the treatment response; thus it
left empty response treatment. Therefore, res-
ponse rate was switched to treatment response
percentage.
Table 1. Demographic Characteristic of Ovarian Cancer
Subjects in Dr. Cipto Mangunkusumo Hospital on the
Period of 2009-2013 
N % 95% CI
Year
< 15 years 0 0 -
15 - 24 years 4 4.1 0 - 9.2
25 - 34 years 13 13.3 7.1 - 20.9
35 - 44 years 21 21.4 13.3 - 30.6
45 - 54 years 33 33.7 24.5 - 44.9
55 - 64 years 19 19.4 11.8 - 27.6
65 - 74 years 8 8.2 3.6 - 15.3
> 74 years 0 0 -
Parity
Nulliparity 30 30.6 22.4 - 38.8
Primiparity 19 19.4 11.3 - 27.7
Multiparity 45 45.9 38.3 - 54.6
Grandemultiparity 4 4.1 1 - 9.2
Menarche
< 12 years 12 14.3 6.6 - 22.6
12 - 16 years 72 85.7 77.4 - 93.4
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Table 2. Clinical Characteristic of Ovarian Cancer
Subjects in Dr. Cipto Mangunkusumo Hospital
on the Period of 2009 - 2013.
N % 95% CI
Stage
I 32 32.7 24.8 - 42.8
II 12 12.2 6.7 - 18.4
III 40 40.8 29.6 - 50.5
IV 14 14.3 7.1 - 20.4
Histotype
Epithelial 75 76.5 67.9 - 86.2
Germinal 13 13.3 5.6 - 19.9
Stromal 10 10.2 4.1 - 16.8
Cytology
Positive 29 38.7 21.3 - 49.4
Negative 32 42.7 32.0 - 53.5
Inconclusive 14 18.7 10.5 - 32.0
Therapy
Surgery 35 35.7 27.1 - 46.9
Surgery followed by adju-
vant chemotherapy 46 46.9 38.3 - 56.6
NeoAdjuvant Chemotherapy -
Surgery - Adjuvant
Chemoterapy 17 17.3 10.2 - 24.5
The distribution of demographic characteristic
subjects were according to age, parity and age of
menarche (Table 1). The distribution of clinical
characteristics were according to staging of newly
diagnosed cases, histopathology results, cytology
results, survival rate based on histopathology, sur-
vival rate based on therapy and clinical response
percentage based on therapy (Table 2).
In epithelial ovarian cancer group, the survival
rate in the first year was 95.8%, second year
86.8%, while it was decreased on the third and
fourth year becoming 77%. Under observation,
there were 74 patients who had completed 1-year
follow up, 55 patients for 2-year follow-up, 29 pa-
tients for 3-year follow-up, while only 13 patients
had completed 4-year follow-up.
In germ-cell tumor group, the first year survival
rate was 91.7% and second to fifth year survival
rate was 83.3%. There were 12 patients completed
1-year observation, 12 patients completed for 2-
year, 7 patients for 3 year and 3 patients for 4-year
observation. Meanwhile, 5-year survival rate of
stromal type group was 100%. The number of pa-
tients who completed 1, 2, 3 and 4 years of obser-
vation were 10, 9, 4, 2 patients, consecutively.
In surgical treatment group, first year survival
rate was 97.1%, second year was 90.6%, third year
was 84.1% and fourth year was 84.1%. There were
35 patients underwent first year, 28 continued to
se-cond year, 13 patients completed the third year
and 4 patients had completed fourth year of obser-
vation.
First year survival rate in surgical with chemo-
therapy as adjuvant therapy group achieved
97.7%, second year was 85.7%, third and fourth
year was 83.3%. There were 45 patients had com-
pleted 1-year observation, then 34 patients left
with 2-year survival, 19 patients completed for the
3-year and 12 patients completed through 4-year
observation.
In neoadjuvant chemotherapy group, first year
and second year of survival rate were 94.1%,
79.9%; respectively and the third and fourth year
were 68.4%. There were 17 patients underwent 1-
year observation, 14 patients continued to 2-year,
8 patients on the 3-year, then 2 patients continued
to 4-year observation.
In the group of surgery followed by adjuvant
chemotherapy, the clinical response based on RE-
CIST criteria showed 63% patients achieved com-
plete response, 4.3% partial response, 4.3% show-
ed progressive disease, 2.2% stable disease, while
there were 26.1% patients were lost to follow up.
Meanwhile, on the group chemotherapy as neo-
adjuvant, it showed 41.2% achieved complete res-
ponse, 11.8% for partial response, 17.6% for pro-
gressive disease and 29.4% patients were lost to
follow-up.
DISCUSSION
National Cancer Institute (NCI) in 2007 had re-
ported that 47.8% of the incidence for ovarian can-
cer occurred in 20-60 years old. In 2015, NCI stated
the incidence had been increasing for above 65
years old.12,13 John K Chan, et al. showed that most
of ovarian cancer (78%) had been diagnosed above
50 years old during the last 14 years. Some studies
stated that the incidence of ovarian cancer in USA
had increased above 64 years old.3,6,7,11 Meanwhile,
in Indonesia, the highest incidence in 2002 was di-
agnosed in 45-54 years old and it was decreased
after that.2 This report described the incidence of
ovarian cancer was varied in Indonesia.
Some studies concluded that age of menarche
was a weak predictor for ovarian cancer. It also
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showed by Whitemore study where they showed
the weak relationship between risk of ovarian can-
cer and menarche age. However, the protective ef-
fect was not found in other studies, whereas Er-
nestoff et al. showed the decreased odd ratio for
11-15 years old was reported not significant.7,14-17
In our study, most of the subjects (73.5%) had their
menarche on 12-16 years old, 14.4% forgot about
their first menstruation and 12.2% started the
menstrual period before 12 years old. The average
menarche age in Indonesia was 12-16 years old.18
Whittemore reported that multiparity women
had lower risk to have ovarian cancer compared to
nulliparity. Based on the population, the highest
protective effect was found in the first term preg-
nancy and increased as the number of parity. It was
also stated that women with history of more than
five pregnancies would decrease the risk of preg-
nancy to 80%.7,15,16 In our study, the most of ova-
rian cancer (45.9%) was diagnosed in multiparity.
The percentage of ovarian cancer would decrease
along with the number of childbirth and the lowest
number was found in grande multiparity subjects.
The declining incidence was 36.7% between nulli-
parity and primiparity and 86.7% between nulli-
parity and grande multiparity.
Another result from this study was most of the
patients were diagnosed in stage III (40.8%). This
result was different compared with previous study
in 2007, whereas most of ovarian cancer cases
(56.52%) were diagnosed in early stage.2
Most of the patients (41.8%) underwent surgical
therapy; other 40.8% underwent surgery and ad-
juvant chemotherapy, while 17.3% received neo-
adjuvant chemotherapy, continued with combina-
tion of surgery and adjuvant chemotherapy. This
was similar to staging distribution from newly di-
agnosed cases. Ovarian cancer stage ≥ IC will need
chemotherapy as adjuvant therapy. This study also
showed most of the patients were diagnosed as ad-
vanced stage; therefore, combination of surgery
and chemotherapy as neo-adjuvant/or adjuvant
therapy would be an alternative therapy.19
National Cancer Institute stated 4-year relative
survival rate of epithelial ovarian tumor in 2007
was 51.5%, 59.3%, 66.8% and 73.6%, respectively.
Meanwhile, 5-year survival rate based on NCI data
in 2011 was 58.7% for less than 65 years old and
28.4% for more than 65 years old. Baldwin, et al.
reported the first, second and fifth year survival
rate for this epithelial type was 65%, 44% and
36%, respectively for American women during
1995 - 2007. Furthermore, Fuh, et al. in 2015
showed Asian had higher survival rate than Ame-
rican women. These results added that ethnic was
relative risk factor for survival rate. Several stu-
dies supported that Asian got higher survival rates
compared with Western population.12,13,21,22
In this study, the result showed the survival rate
for epithelial tumor in Dr. Cipto Mangunkusumo
Hospital was higher than the previous studies. It
was hypothesized that ethnic and majority of
younger age compared to American women played
role to the results. The type of ovarian cancer as
well as differentiation was also contributed to sur-
vival results. The weakness of this study was ma-
jority of lost to follow up patients that might cause
the accuracy of survival analysis.
Study performed by Chan, et al. stated 5-year
survival rate of germ cell tumor achieved 94.7% in
2006 and NCI data had supported the similar re-
sults for 85% survival rates.3,12,13 Meanwhile, this
study showed the first, second and fourth year sur-
vival rate were 91.7%, 83.3% and 83.3%, respec-
tively. This difference might be caused of limitation
subjects (13 subjects) included to this group.
Other findings for stromal type had achieved
100% 5-year survival rate. Some studies showed
5-year survival rate of germ cell tumor in general
was more than 85%. The weakness of this study
was small number of subjects (10 subjects).4,12,19
On the surgery group, the results of 1-, 2-, 3-, 4-
year survival rates were 97.1%, 90.6%; 84.1% and
84.1%, respectively. On literature, surgery was per-
formed to low risk ovarian cancer (stage IA-IB)
with well differentiated. Surgical only had achieved
90% of curative stage and 5-year survival rate
78%. The success of therapy was decided if optimal
surgery results achieved.11,20 Trimbos, et al. stated
that adequate surgical staging and degree of dif-
ferentiation were the significant prognostic fac-
tors, instead of staging.20
The treatment response of ovarian cancer stage
≥ IC after adjuvant chemotherapy was determined
by amount and size of tumor implant after surgical
staging.19,23 Based on ACTION and ICON study, 5-
year survival rate after chemotherapy as adjuvant
therapy was 82%, and 74%.19 In this study, sur-
vival rate of patient underwent surgery continued
by adjuvant therapy was 97.7% in first year and
87.5% in the second year, also 83.3% from third
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and fourth year. However, this study did not in-
clude the operation result.
Chemotherapy as neo-adjuvant treatment is in-
dicated to ovarian cancer with the lowest predic-
tion to achieve optimal cyto-reduction after sur-
gery. The other indication is ovarian cancer stage
IIIC with ascites >500cc. One of the advantages
from neo-adjuvant admission is low morbidity due
to surgical procedure. Yet, the result to survival
rate is unclear. Several studies showed no differ-
ence among survival rates, but the patients had
better quality of life. Multicenter study in France
showed survival improvement in neo-adjuvant
group, while it showed no significant results in Ja-
pan. The most important prognostic factor to res-
ponse of chemotherapy as neo-adjuvant therapy
was if it was optimal or suboptimal-debulking.
Bilici, et al. stated 50% patients would achieve 52.5
month length of life with optimal cyto-reduc-
tion.19,23
Furthermore, previous study reported 2-year
survival rate in neo-adjuvant group was 90%. This
study showed similar results, that first year of sur-
vival rate was 94.1% and 5-year survival rate of
neo-adjuvant chemotherapy was only 68.4%. The
reason was due to the limitation number of sub-
jects.
Another result from combination of surgery
and adjuvant chemotherapy group were 65.8%
achieving complete response. Neo-adjuvant che-
motherapy group showed 41.2% patients achiev-
ing complete response. Based on references, more
than 50% in advanced stage patients whom re-
ceived paclitaxel and carboplatin chemotherapy
showed complete response, only 20-30% subjects
could achieved partial response or progressive
disease.24
CONCLUSION
The highest incidence of ovarian cancer in Dr. Cipto
Mangunkusumo Hospital belongs to the age of re-
productive women (≤ 55 years old) with the highest
incidence occurs in nulliparity women. Most of the
ovarian cancer cases are diagnosed in advanced
stage (stage III-IV).
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